Some of the first functions to decline during this process are IL-2 production and ex vivo killing abilities. For 10 points each:
[10m] Name this process during which persistent viral or tumor-mediated antigenic stimulation of T cells causes attenuation of their effector functions. Unlike anergy, high expression of Tox is associated with this process.
ANSWER: T cell exhaustion [accept CD8+ T cell exhaustion or CD4+ T cell exhaustion; accept word forms of exhaust in place of “exhaustion”]
[10e] In the setting of HCV or HBV infection, higher values of this quantity correlate to more severe T cell exhaustion. NAAT tests for HIV measure this quantity that is given in RNA copies per milliliter.
ANSWER: viral load [or viral burden; or viral titre or viral titer; accept peak viremia]
[10h] Tumors-mediated T cell exhaustion represents a major limit to this form of therapy that can currently treat relapsed or refractory multiple myeloma, follicular lymphoma, and acute lymphoblastic leukemia.
ANSWER: CAR-T therapy [or chimeric antigen receptor T-cell therapy; accept adoptive cell therapy or ACT; prompt on chimeric antigen receptors or CARs or chimeric immunoreceptors; prompt on cancer immunotherapy]
<Biology>